Latest News about Psilocybin program

Recent news which mentions Psilocybin program

< Previous 1 2 Next >

Compass' Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows

July 25, 2023

Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials

July 24, 2023

Filament Health Uplisting To NASDAQ In A $210M SPAC Deal

July 19, 2023

Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'

July 18, 2023

Filament Supplies Botanical Psilocybin To Canadian Researchers, Inks Global Licensing Deal

July 07, 2023

Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific

June 12, 2023

From The U.S. To Canada: High-Quality Psilocybin API Gets Green Light For Import

June 12, 2023

Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia

June 09, 2023

Colorado Media Buzz On Psychedelic Mushroom Businesses, This Company Offers 'Top Rare' Strains

June 02, 2023

UCSF Clinical Trial Shows Promising Results For Naturally-Sourced Psilocybin And Psilocin

May 30, 2023

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD

May 30, 2023

Washington State Psychedelics Trial Targets PTSD And Alcohol Use Disorder, Mandated By Law

May 23, 2023

Link Between Cancer And Psilocybin: Research On This Palliative Promise

May 22, 2023

This Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History

May 19, 2023

EXCLUSIVE: Lessons From Psychedelics Markets Through Business, Legal And Reciprocity Lenses

May 12, 2023

COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials

May 11, 2023

International IP Claims On Novel Psychedelic Fungi Biomass Manufacturing Gets Prelim Acceptance

May 03, 2023

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More

April 05, 2023

Therapists At Mass General Hospital Prepared To Assist IBS Patients With Psilocybin Therapy

April 04, 2023

Filament Health: 2022 Financials And Operational Highlights From Creator Of The Ayahuasca Pill

April 03, 2023

COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression

March 14, 2023

Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla

March 06, 2023

COMPASS Pathways Shares Q4 & Year-End 2022 Financials, Advances Phase 3 Psilocybin Trials

February 28, 2023

2C-B Vs. Psilocybin: New Study Shares Insightful Trial Results On The Mescaline-Derived Psychedelic's Effects

February 21, 2023

State-Level Psychedelics In 2023: Oklahoma Introduces Research Bill, Washington Amends And Passes Measure

February 17, 2023

Supply Partnerships: Filament's Psilocybin Trial In Canada, PharmAla's MDMA Program In Australia

February 14, 2023

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

February 14, 2023

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More

February 13, 2023

Testing Psychedelics Efficacy On 'Psychiatry's Blind Spot': Latest King's College Trial

February 13, 2023

How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out

February 09, 2023

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.